<DOC>
	<DOCNO>NCT00402051</DOCNO>
	<brief_summary>This two-arm , parallel , open-label , Phase 2 multicenter study pemetrexed first line combination therapy either cisplatin carboplatin palliative setting stage IIIb IV non-small cell lung cancer patient . Approximately 130 patient include 15 center Germany randomize one treatment regimens 1:1 ratio . Chemotherapy administer maximum six cycle standard length 21 day . Primary objective Progression Free Survival Time patient assess treatment arm .</brief_summary>
	<brief_title>Chemotherapy With Pemetrexed Combination With Platinum Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Cytologically and/or histologically confirm NSCLC Stage IIIb IV No previous systemic chemotherapy cancer At least one unidimensionally measurable lesion meeting Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 adequate organ function Prior radiation therapy allow limited &lt; 25 % patient 's bone marrow Serious concomitant systemic disorder active infection Mild moderate renal insufficiency , unable interrupt salicylate nonsteroidal antiinflammatory drug Symptomatic central nervous system ( CNS ) metastases require concurrent corticosteroid therapy Presence clinically significant thirdspace fluid collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>